Improvement in Immune Cell Function in Elderly Humans
Conditions
Brief summary
A randomized, double blind placebo-controlled parallel intervention in adults over the age of 50 will be performed. Participants will receive a supplement capsule containing placebo (Crystalline Cellulose) or 500mg of Setria® Glutathione to eat for 120 days. Glutathione is hypothesized to replenish the body's reserves that may be depleted through natural aging process, poor diet, or due to the detoxification process for drugs. The primary end point is the number of healthy days experienced during the duration of the study. Secondary endpoints include cellular and biochemical measures from blood samples taken before and after the study.
Detailed description
The long term goal of this investigation is to understand how food components improve immune function, both in its ability to respond to pathogens and its ability to turn off when the response is no longer needed. The goal of this application is to examine mechanisms by which glutathione improves immune cells after consumption. The central hypothesis is that glutathione improves redox status within the cell, thereby improving cell function and increasing the number of healthy days experienced by the participants. After obtaining informed consent, human participants will receive 500 mg/day of Setria® Glutathione or placebo for 120 days. Peripheral blood mononuclear cells (PBMC), neutrophils and serum will be obtained from blood draws before and after the 120 days. A daily diary of illness will be kept by each participant and will record any incidence of illness, the number of symptoms per incidence, and the number of days in which symptoms are present. This study is powered on the basis that over 120 days, the glutathione-supplemented group would experience 3% more healthy days compared to the placebo group. The analysis indicated 60 people per group.
Interventions
DIETARY_SUPPLEMENTSetria glutathione supplement
500 mg/day capsule taken in the morning for 120 days.
DIETARY_SUPPLEMENTCrystalline Cellulose
500 mg/day capsule taken in the morning for 120 days.
Sponsors
Kyowa Hakko Bio Co., Ltd.
University of Florida
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* generally healthy * must have had at least one cold during the previous year * age 50-75 * must discontinue other dietary supplement use
Exclusion criteria
* on arthritis medication * on hypertension medication * severe allergies * compromised immune system * high cholesterol, heart failure, angina, etc. * diagnoses of diabetes or metabolic syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Severity and frequency of Cold / Flu symptoms | 120 days | Participants will record any cold / flu symptoms in log throughout the study duration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of immune cell function | 120 days | Increased neutrophil respiratory burst; IFN-gamma and other cytokine production measurements; gd-T cell proliferation in mitogen-stimulated ex vivo culture |
Countries
United States
Outcome results
None listed